Biennial survey finds growing awareness of information options by consumers
    Patients' trust of information from the pharma industry has doubled--from 9 to 18% of those surveyed--since 2010; but it's still the lowest among competing sources such as pharmacies, hospitals and medical practitioners, with the latter having the highest rating of 49%. That's one of the eyecatching results from the 2015 Survey of Health Care Consumers, conducted by the Deloitte Center for Health Solutions. The survey, based on a statistically grounded cross-section of the US public, looks at overall trends in healthcare consumerism
    Besides new traceability software, SAP floats the idea of a connected 'Pharma Network'
    The battleground for IT solutions to meet the requirements of the Drug Supply Chain Security Act (DSCSA), as well as similar traceability regulations coming into force around the world, is heating up. On Sept. 15, SAP formally launched ATTP, propelled by a collaboration with nine of the top 20 pharma companies and a major US wholesaler. The software enables pharma manufacturers to generate serial numbers (random ones if desired), transmit those serial codes to packaging lines, and then track the disposition of the coded unit
    While mHealth apps have more than doubled in quantity, industry and healthcare providers are still figuring out what their value is
    Mobile health (mHealth) apps will either revolutionize healthcare or be the latest smartphone/social-media/Internet fad--or, most likely, something in between. Definitions are still fluid: is a jogging distance tracker as medically meaningful as a monitor of drug levels in the bloodstream? The IMS Institute for Health Informatics (Parsippany, NJ), in the update of a 2013 study, uses the WHO definition: "medical and public health practice supported by mobile devices such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other wireless devices," which encompasses many wellness or
    Kansas physicians love their rep visits; Wisconsinites, not so much...
    The 2015 AccessMonitor, a proprietary data source of ZS Associates (Evanston, IL) shows a continued slide in rep access--now the majority (53%) of physicians are "access restricted," which ZS defines as meeting with 31-70% of reps who call on them. The 2014 figure was 49%; in 2008, the first year ZS began studying the topic, only 23% of physicians restricted access. This trend is well known in the industry, but ZS ferrets out some factors that are driving access down: one is health system consolidation. ZS compared 20 metro markets
    Initial pricing has a 15% discount off Amgen's Neupogen
    Some are calling it a "new era in biotechnology," which is debatable, but in any case, Novartis' Sandoz unit has now cleared the last bit of legal wrangling with Amgen and will now market the product in the US. Press reports indicate that Sandoz will price the drug at a 15% discount to Neupogen. For the moment (until FDA finalizes its proposed naming conventions for biosimilars), the Sandoz product is branded as Zarxio (filgrastim-sndz). Zarxio (or, in Europe, Zarzio) isn't the only biosimilar; Teva Pharma went the route of conducting its own R&D and approval program to commercialize Granix, its version of filgrastim, and there are other biosimilar filgrastims
    Annual survey ranks Good Neighbor Pharmacy as No. 1
    The consumer-sentiment surveyor J.D. Power and Associates (Westlake Village, CA) finds Good Neighbor Pharmacy, the franchise organization run by AmerisourceBergen, on top among chain and independent pharmacies nationally. By measuring five factors (prescription ordering; store; cost competitiveness; non-pharmacist staff; and pharmacist) and ranking on a 1000-point scale, J.D. Power puts Good Neighbor at 876, just nosing out Health Mart (McKesson's similar franchising operation), at 875, and the Medicine Shoppe (a franchising organization owned by Cardinal Health) at 861. The average for all chains was 842, while supermarket pharmacies came in at 851
    Projected to grow 9% (CAGR) through 2020
    Laboratory rats are such a common element of drug research that the term is also used for those who work in the field. And while there are many, many drugs that showed promise during this form of animal testing but later failed (and despite the efforts of animal activists to restrict the activity), lab rats are still an essential tool for researchers. Marketsandmarkets, a Pune, India, market research firm, has just announced a study putting the overall business at $358 million in 2014, rising to $602 million by 2020. And, just as, say, chromatographs come in varieties like liquid, gas, high-pressure and such, lab rats come in a growing variety
    50% expansion adds to facility's pharma capacity; emphasis on cold chain services
    Kuehne + Nagel, one of the largest global logistics companies, has built up its KN PharmaChain brand of healthcare logistics solutions in recent years, with its Contract Logistics division sharing in the growth of this overall category. Now, it is adding roughly 50% more capacity to its Memphis, TN facility, which already has over 200,000 sq. ft. of warehouse capacity, mostly dedicated to life sciences. A 10-year contract with an unspecified client has enabled the company to add 117,000 sq. ft, including 36,800 for 2-8C service, 24,500 for -25C cryogenic service, and 43,000 for controlled-ambient conditions. An additional 20,000 sq. ft. is available for packaging
    Sofrigam promotes its Igloo kit for pharmacy-to-home; Sonoco, a new reusable container
    Years ago (and, worrisomely, in some cases still today) pharma cold chain packaging amounted to beer coolers with some ice thrown in, but the field has advanced dramatically over the past decade with highly engineered containers and cooling technologies. Now, specialized containers for specific parts of the distribution channels of life sciences products are appearing. The latest involve the critical "last mile" delivery to the patient's home, and economical and dependable shipping of blood products. In the latter case, Sonoco ThermoSafe (Arlington Heights, IL) has announced the Via reusable
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the September/October 2015 Issue now - It's Free!
Pharmaceutical Commerce’s annual Cold Chain Sourcebook projects 44% growth over the 2013–2019 span
Pharmaceutical Commerce sat down with Steve Collis, president and CEO of AmerisourceBergen since 2011, to see how the WBA partnership is going, and what lies ahead for the company. Here’s what he had to say.
Contract development and manufacturing organizations (CDMOs) want to be more reliable business partners to pharma  continued >
More volumes of more valuable products drive growth  continued >
Data-driven applications provide corresponding value based on the role and goal of the user  continued >
While the biopharma industry continues to develop better treatment options, there is a stronger focus on more intensive patient engagement  continued >
New IT tools are propelling a more focused approach to product launch  continued >
Cold Chain 2015 Directory
Looking for a 'paradigm shift' in patient recruitment and retention on an international level 
  |     |     |     |     |     |  
©2015 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.